Vasomedical's EECP® Therapy to be Featured Treatment at Stony Brook Medicine's New Cardiovascular Wellness and Preventive Research Center

WESTBURY, N.Y., June 12, 2013 /PRNewswire/ -- Vasomedical, Inc. (OTC BB: VASO) announced today that Stony Brook Medicine's new Center for Cardiovascular Wellness and Preventive Research will feature the Company's EECP Therapy devices in the treatment of vascular endothelial dysfunction and in preventing the onset and progression of cerebral, coronary and peripheral vascular diseases.

According to Stony Brook Medicine's public announcement, the center was made possible as a result of several recent philanthropic gifts that were matched dollar for dollar by the Simons Foundation Challenge Grant, doubling their impact and totaling in excess of $7.5 million. The center will conduct groundbreaking research into cardiovascular health and to identify and develop new options for the treatment and prevention of coronary artery disease, heart failure and Alzheimer's disease.  It will focus on EECP Therapy, an FDA-cleared, non-invasive therapeutic device manufactured by Vasomedical that reduces the workload of the heart and increases blood flow to the coronary arteries and other organs of the body.

Dr. Michael Poon, a professor of Emergency Medicine, Medicine (Cardiology), and Radiology, and Director of Advanced Cardiovascular Imaging at Stony Brook Medicine, is leading the research efforts at the new center.  Research at the center could ultimately benefit not only patients with or at risk of developing coronary artery disease, but also heart failure and Alzheimer's disease, which are disorders that could be caused by vascular endothelial dysfunction, as the results are translated into new approaches to patient care and disease prevention.  Additional exploratory research will examine the use of EECP Therapy in preventing muscle soreness and injury in elite athletes.

"At Vasomedical, we have been proponents of EECP Therapy for almost 20 years, seeing incredible benefits to many different patient populations.  Stony Brook University was among the first in the United States to adopt EECP Therapy as a noninvasive treatment for cardiac ailments and has participated in many published studies. We are grateful for Stony Brook University and Dr. Poon's continued support and commitment to the research with our innovative devices," said Dr. John Hui, Chief Technology Officer of Vasomedical, Inc. "We look forward to seeing the results of their studies, and are pleased that such a reputable institution is working to raise public awareness and support a technology with the potential to revolutionize the cardiovascular health industry."

Since 1992, there have been more than 190 papers published in peer-reviewed journals demonstrating the safety, efficacy, mechanisms of actions as well as economic outcome of EECP Therapy. Published clinical studies have also shown that EECP Therapy reduces arterial stiffness, improves cardiovascular and cerebral health and has a significant effect on improving patients' quality of life.  The Therapy is covered by Medicare and most private insurance companies for the treatment of refractory angina.

About Vasomedical
Vasomedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products.  The Company's main proprietary products are EECP^® Therapy systems, the gold standard of ECP treatment. The Company operates through three wholly owned subsidiaries: VasoSolutions, Vasomedical Global and VasoHealthcare. VasoSolutions manages and coordinates the design, manufacture and sales of EECP® Therapy systems, and other medical equipment operations; Vasomedical Global operates the Company's China-based subsidiaries; and VasoHealthcare is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain market segments. Additional information is available on the Company's website at www.vasomedical.com.

Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as "anticipates", "believes", "could", "estimates", "expects", "may", "plans", "potential" and "intends" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.

Investor Contacts:
Todd Fromer / Garth Russell
KCSA Strategic Communications
212-896-1215 / 212-896-1250
[email protected] / [email protected]  

SOURCE Vasomedical, Inc.